Kamada (NASDAQ:KMDA) Stock Breaks Below 200-Day Moving Average – What’s Next?

Kamada Ltd. (NASDAQ:KMDA – Get Free Report) passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $7.99 and traded as low as $7.76. Kamada shares last traded at $7.8340, with a volume of 158,516 shares.

Wall Street Analysts Forecast Growth

KMDA has been the subject of several recent analyst reports. Weiss Ratings lowered Kamada from a “buy (b)” rating to a “buy (b-)” rating in a report on Monday, November 9th. UBS Group reaffirmed a “buy” rating and set a $15.00 price target on shares of Kamada in a research report on Friday, September 18th. Wall Street Zen upgraded Kamada from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 15th. Finally, Stifel Nicolaus set a $12.00 price objective on Kamada in a research report on Monday, November 9th. Four research analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $13.75.

Read Our Latest Stock Analysis on Kamada

Kamada Stock Down 1.1%

The firm has a market cap of $445.13 million, a P/E ratio of 18.00, a price-to-earnings-growth ratio of 0.68 and a beta of 0.90. The firm’s 50-day simple moving average is $8.03 and its 200 day simple moving average is $7.99.

Kamada (NASDAQ:KMDA – Get Free Report) last released its earnings results on Monday, November 9th. The biotechnology company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.01. Kamada had a net margin of 12.67% and a return on equity of 9.36%. The firm had revenue of $52.03 million for the quarter, compared to analysts’ expectations of $52.51 million. As a group, analysts forecast that Kamada Ltd. will post 0.48 earnings per share for the current year.

Kamada Announces Dividend

The business also recently declared a special dividend, which will be paid on Wednesday, December 9th. Investors of record on Thursday, November 19th will be issued a $0.14 dividend. The ex-dividend date of this dividend is Thursday, November 19th. Kamada’s payout ratio is 30.23%.

Hedge Funds Weigh In On Kamada

Several institutional investors and hedge funds have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. boosted its holdings in Kamada by 14.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,527 shares of the biotechnology company’s stock worth $92,000 after buying an additional 1,346 shares during the period. Aristides Capital LLC raised its holdings in Kamada by 4.5% during the 1st quarter. Aristides Capital LLC now owns 34,491 shares of the biotechnology company’s stock valued at $288,000 after acquiring an additional 1,476 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in Kamada during the 3rd quarter valued at $25,000. State of Tennessee Department of Treasury bought a new stake in Kamada during the 3rd quarter valued at $60,000. Finally, Marshall Wace LLP lifted its position in shares of Kamada by 150.1% during the third quarter. Marshall Wace LLP now owns 188,037 shares of the biotechnology company’s stock worth $1,591,000 after acquiring an additional 112,855 shares in the last quarter. 20.38% of the stock is owned by institutional investors.

About Kamada

(Get Free Report)

Kamada Ltd. is an Israeli biopharmaceutical company that develops, manufactures and markets plasma-derived therapies and specialty pharmaceutical products. Founded in 1990, the company is headquartered in Rehovot, Israel. Its products include Glassia, an alpha-1 proteinase inhibitor used to treat people with alpha-1 antitrypsin deficiency, and immune globulin therapies for conditions including rabies exposure, cytomegalovirus infection and varicella-zoster exposure. Kamada serves markets in the United States and internationally, selling products directly and through commercial partners.

See Also

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.